Hua Medicine (HKSE:02552) Current Deferred Revenue : HK$0.0 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Hua Medicine Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Hua Medicine's current deferred revenue for the quarter that ended in Dec. 2024 was HK$0.0 Mil.

Hua Medicine Current Deferred Revenue Historical Data

The historical data trend for Hua Medicine's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hua Medicine Current Deferred Revenue Chart

Hua Medicine Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Deferred Revenue

Get a 7-Day Free Trial

Hua Medicine Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Current Deferred Revenue	Get a 7-Day Free Trial												-	-	-	-	-

Hua Medicine Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Hua Medicine's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Hua Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hua Medicine (HKSE:02552) » Definitions » Current Deferred Revenue

Traded in Other Exchanges

N/A

Address

Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203

Website

https://www.huamedicine.com

Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from PRC.

Executives

Hong Jane Xingfang	2202 Interest of your spouse
Chen Li	2101 Beneficial owner
Hlyy Limited	2306 Nominee for another person
Tct (bvi) Limited	2501 Other
The Core Trust Company Limited	2301 Trustee
Wuxi Pharmatech Investments (cayman) Inc.	2201 Interest of corporation controlled by you
Wuxi Pharmatech Investment Holdings (cayman) Inc.	2201 Interest of corporation controlled by you
Wuxi Pharmatech Fund I General Partner L.p.	2201 Interest of corporation controlled by you
Wuxi Pharmatech Healthcare Fund I L.p.	2101 Beneficial owner
Wuxi Apptec Co., Ltd.	2201 Interest of corporation controlled by you
Wuxi Apptec International Holdings Limited	2201 Interest of corporation controlled by you
Nelsen Robert Taylor	2101 Beneficial owner
Venrock Management V, Llc	2102 Investment manager
Harvest Yuanxiang (cayman) Limited	2101 Beneficial owner
Arch Venture Fund Vii, L.p.	2101 Beneficial owner

Hua Medicine Headlines

No Headlines